Grifoni Alba, Angelo Michael, Sidney John, Paul Sinu, Peters Bjoern, de Silva Aruna D, Phillips Elizabeth, Mallal Simon, Diehl Sean A, Botten Jason, Boyson Jonathan, Kirkpatrick Beth D, Whitehead Stephen S, Durbin Anna P, Sette Alessandro, Weiskopf Daniela
Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Genetech Research Institute, Colombo, Sri Lanka.
J Virol. 2017 Mar 29;91(8). doi: 10.1128/JVI.02133-16. Print 2017 Apr 15.
A deletion variant of the dengue virus (DENV) serotype 2 (DENV2) Tonga/74 strain lacking 30 nucleotides from its 3' untranslated region (rDEN2Δ30) has previously been established for use in a controlled human DENV challenge model. To evaluate if this model is appropriate for the derivation of correlates of protection for DENV vaccines on the basis of cellular immunity, we wanted to compare the cellular immune response to this challenge strain to the response induced by natural infection. To achieve this, we predicted HLA class I- and class II-restricted peptides from rDEN2Δ30 and used them in a gamma interferon enzyme-linked immunosorbent spot assay to interrogate CD8 and CD4 T cell responses in healthy volunteers infected with rDEN2Δ30. At the level of CD8 responses, vigorous responses were detected in approximately 80% of donors. These responses were similar in terms of the magnitude and the numbers of epitopes recognized to the responses previously observed in peripheral blood mononuclear cells from donors from regions where DENV is hyperendemic. The similarity extended to the immunodominance hierarchy of the DENV nonstructural proteins, with NS3, NS5, and NS1 being dominant in both donor cohorts. At the CD4 level, the responses to rDEN2Δ30 vaccination were less vigorous than those to natural DENV infection and were more focused on nonstructural proteins. The epitopes recognized following rDEN2Δ30 infection and natural infection were largely overlapping for both the CD8 (100%) and CD4 (85%) responses. Finally, rDEN2Δ30 induced stronger CD8 responses than other, more attenuated DENV isolates. The lack of a known correlate of protection and the failure of a neutralizing antibody to correlate with protection against dengue virus have highlighted the need for a human DENV challenge model to better evaluate the candidate live attenuated dengue vaccines. In this study, we sought to characterize the immune profiles of rDEN2Δ30-infected subjects and to compare the profiles with those for subjects from areas where DENV is hyperendemic. Our data demonstrate that T cell responses to rDENV2Δ30 are largely similar to those to natural infection in terms of specificity, highlighting that the response to this virus in humans is appropriate as a model for the T cell response to primary DENV2 infection.
登革病毒2型(DENV2)汤加/74株的一种缺失其3'非翻译区30个核苷酸的缺失变异株(rDEN2Δ30)先前已被构建用于可控的人类登革病毒攻击模型。为了评估该模型是否适合基于细胞免疫推导登革病毒疫苗的保护相关性,我们想将对该攻击株的细胞免疫反应与自然感染诱导的反应进行比较。为实现这一目的,我们预测了rDEN2Δ30的HLA I类和II类限制性肽,并将其用于γ干扰素酶联免疫斑点试验,以检测感染rDEN2Δ30的健康志愿者的CD8和CD4 T细胞反应。在CD8反应水平上,约80%的供体检测到强烈反应。这些反应在强度和识别的表位数量方面与先前在登革病毒高度流行地区供体的外周血单个核细胞中观察到的反应相似。这种相似性延伸到登革病毒非结构蛋白的免疫优势等级,NS3、NS5和NS1在两个供体队列中均占主导地位。在CD4水平上,对rDEN2Δ30疫苗接种的反应不如对自然登革病毒感染的反应强烈,且更集中于非结构蛋白。rDEN2Δ30感染和自然感染后识别的表位在CD8(100%)和CD4(85%)反应中大部分重叠。最后,rDEN2Δ30诱导的CD8反应比其他减毒程度更高的登革病毒分离株更强。缺乏已知的保护相关性以及中和抗体与登革病毒保护作用不相关,凸显了需要一个人类登革病毒攻击模型来更好地评估候选减毒活登革疫苗。在本研究中,我们试图描述rDEN2Δ30感染受试者的免疫特征,并将这些特征与登革病毒高度流行地区受试者的特征进行比较。我们的数据表明,T细胞对rDENV2Δ30的反应在特异性方面与对自然感染的反应基本相似,这突出表明人类对该病毒的反应适合作为T细胞对原发性DENV2感染反应的模型。